IGHG3 and infection: This effect was most noticeable for Plasmodium vivax asymptomatic infections as IGHG3*30 carriers had on average one fewer infection in the 18-month follow-up period as compared to non-IGHG3*30 allele carriers (β= -1.06; 95% CI [-2.01, -0.12], p=0.028).